{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-001884","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.648281+00:00","generated_at":"2026-06-07T04:09:47.470911+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kymera unveils STAT6 degrader KT-621 (Phase 1 in H2 2024) and TYK2 degrader KT-294 (Phase 1 in H1 2025)","bullets":["KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.","KT-294 (TYK2 degrader) planned to enter Phase 1 in H1 2025; potential to recapitulate TYK2 loss-of-function biology.","KT-474 (IRAK4 degrader) Phase 2 enrollment in HS and AD expected to complete Q4 2024; topline data H1 2025.","Both KT-621 and KT-294 are wholly-owned, once-daily oral degraders targeting validated autoimmune pathways.","Company holds virtual R&D Day on Jan 4, 2024 to present immunology strategy and new preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-001884","json":"https://secwatch.observer/filing/0001193125-24-001884.json","markdown":"https://secwatch.observer/filing/0001193125-24-001884.md","text":"https://secwatch.observer/filing/0001193125-24-001884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/0001193125-24-001884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/d378650d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:09:47.470911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}